Scarica l'app Stockscreener
22.28
2.28%
-0.52
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DNLI Giù?
Forum
Previsione
Denali Therapeutics Inc Borsa (DNLI) Ultime notizie
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript - AOL.com
145,045 Shares in Denali Therapeutics Inc. $DNLI Purchased by Great Lakes Advisors LLC - MarketBeat
Denali’s DNL921 Trial: Early Alzheimer’s Safety Data That Could Shape Long-Term Upside - TipRanks
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock? - TradingView
Edmond DE Rothschild Holding S.A. Invests $4.25 Million in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali (DNLI) Financial Update: The Available Earnings Metric Delivers a Miss for This Review; Market Reaction: Shares Finish 3.25% UpDividend Increase Stocks - vinanet.vn
Denali Therapeutics: Bullish On AVLAYAH And Their Prospects (NASDAQ:DNLI) - Seeking Alpha
Bank of America Corp DE Boosts Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (DNLI) Could Be 42% Undervalued Following Its Earnings Report - Sahm
SCS Capital Management LLC Takes Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics CEO Ryan J. Watts Donates 32,220 Shares to Donor Advised Fund - Kalkine Media
Denali Therapeutics Inc.: Fundamental Analysis and Financial Ratings | DNLI | US24823R1059 - marketscreener.com
Denali Therapeutics (NASDAQ:DNLI) Insider Sells $71,624.99 in Stock - MarketBeat
Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One (NASDAQ:DNLI) - Seeking Alpha
Sei Investments Co. Purchases Shares of 52,235 Denali Therapeutics Inc. $DNLI - MarketBeat
J.P. Morgan Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Equities Analysts Set Expectations for DNLI Q3 Earnings - MarketBeat
E. Ohman J or Asset Management AB Acquires New Shares in Denali Therapeutics Inc. $DNLI - MarketBeat
Baillie Gifford Trims Denali Therapeutics (DNLI) Stake in June R - GuruFocus
Weekly Recap: Q2 revenue, big net loss and DNL126 Phase 3 with 2027 BLA - TradingView
Denali climbs past Avlayah expectations with $3.6M in revenue - BioSpace
(DNLI) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
The Manufacturers Life Insurance Company Lowers Stock Holdings in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Posts Earnings Results, Misses Estimates By $0.17 EPS - MarketBeat
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $42 - Moomoo
Denali Therapeutics (DNLI) Is Up 7.9% After AVLAYAH Launch Drives First Full-Quarter Commercial Revenue - Sahm
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Stock Rating Upgraded by Wall Street Zen - MarketBeat
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum - Yahoo Finance
UBS Adjusts Price Target on Denali Therapeutics to $34 From $25, Maintains Buy Rating - marketscreener.com
Denali Therapeutics Inc. Stock 12‑Month Price Target Raised to $35.44, Implies 43% Upside - TradingView
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $41 - Moomoo
Denali Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Wedbush Adjusts PT on Denali Therapeutics to $27 From $26, Maintains Outperform Rating - marketscreener.com
Earnings call transcript: Denali Therapeutics posts Q2 2026 revenue miss as AVLAYAH launch builds - Investing.com Nigeria
Denali Therapeutics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:DNLI) 2026-08-07 - Seeking Alpha
DNLI SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Denali Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Denali Therapeutics Q2 Earnings Call Highlights - MarketBeat
Denali Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
Denali Q2 2026 earnings: AVLAYAH debuts with $3.6 million in revenue - TradingKey
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (DNLI) Denali Therapeutics Posts Q2 Loss of $0.68, vs. FactSet Est of $0.51 Loss - marketscreener.com
Denali Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (DNLI) Denali Therapeutics Inc. Reports Q2 Revenue $3.6M, vs. FactSet Est of $2.2M - marketscreener.com
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - The Manila Times
Denali Therapeutics reports $3.6M in Q2 2026 product revenue, pro forma cash >$1.1B - TradingView
Denali Therapeutics Inc. 2026: Revenue $3.6M, EPS ($0.68) — 10-Q Summary - TradingView
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise - TradingView
Denali Therapeutics (NASDAQ: DNLI) posts Q2 loss and launches AVLAYAH - Stock Titan
BRIEF-Denali Therapeutics Q2 Operating Expenses USD 134.145 Million - TradingView
Denali Therapeutics earnings on deck: First drug sales in focus By Investing.com - Investing.com Nigeria
Denali Therapeutics Inc. (DNLI) Stock Analysis: Investors Eye 48% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
Baillie Gifford & Co (DNLI) reports 7.54% stake in Denali Therapeutics common stock - Stock Titan
Dimensional Fund Advisors LP Boosts Stock Holdings in Denali Therapeutics Inc. $DNLI - MarketBeat
Groupama Asset Managment Grows Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (DNLI) to Release Earnings on Thursday - MarketBeat
Denali Therapeutics Inc. $DNLI is ADAR1 Capital Management LLC's 10th Largest Position - MarketBeat
Denali Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Denali Therapeutics sells priority review voucher for $195 million gross proceeds - Bitget
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026 - The Manila Times
Denali Therapeutics Inc (DNLI) Cash Flow - TradingKey
Denali sets Aug. 6 webcast on medicines crossing the blood-brain barrier - Stock Titan
Denali Therapeutics Inc (DNLI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):